XCUR
Exicure, Inc.
Healthcare — Biotechnology
Exicure, Inc. does not have significant operations. Previously, it focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. The company has a co-development agreement with Adbiotech Co., Ltd. to explore combination therapies based on Burixafor (GPC-100) across multiple therapeutic areas. Exicure, Inc. was founded in 2011 and is headquartered in Redwood City, California.
None
$1.12
$-0.07 (-5.59%)
Price History
52-Week Range
Sign in to add XCUR to a watchlist or set price alerts.
Fundamentals
| Market Cap | $10.20M |
| P/E Ratio (TTM) | - |
| Forward P/E | -2.08 |
| EPS (TTM) | $-1.57 |
| Dividend Yield | - |
| Profit Margin | - |
| Revenue Growth | - |
| ROE | -145.16% |
| Debt/Equity | 1.05 |
| Recommendation | None |
| Analyst Target | - |
| Analysts | - |
| Next Earnings | - |
| Indexes | - |
Technical Indicators
| RSI (14) | 47.4 |
| Beta | 3.60 |
| SMA 20 | $1.75 |
| SMA 40 | $2.14 |
| 52-Week High | $9.48 |
| 52-Week Low | $1.43 |
| 50-Day Avg | $2.31 |
| 200-Day Avg | $3.93 |
| Avg Volume | 396.3K |
| Volume | 17.6K |
Performance Analysis
NEUTRALXCUR presents a mixed picture with both positive and negative indicators.
+
Trading near its 52-week low ($1.43), which could present a value opportunity.
~
RSI at 47.4 is in neutral territory.
-
Price is below both the 50-day and 200-day moving averages — in a downtrend.
~
Wall Street consensus is "none".
Recent News
Loading news...
Last updated: Aug 01, 2026 04:16 UTC
Back to Screener Export Report